

CITATION REPORT

List of articles citing

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

DOI: 10.1097/00045391-200103000-00003

American Journal of Therapeutics, 2001, 8, 85-95.

Source: <https://exaly.com/paper-pdf/32718978/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
302	A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. 2001 , 23, 1478-91		89
301	Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. 2001 , 38, 1145-57		58
300	COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?. 2001 , 30, 1011-25, viii		15
299	Cyclooxygenase-2 Inhibition and Renal Function. 2001 , 134, 1078		2
298	Pharmacological therapies for the treatment of osteoarthritis. 2001 , 175, S108-11		9
297	Cardiovascular and renal effects of COX-2-specific inhibitors: recent insights and evolving clinical implications. <i>American Journal of Therapeutics</i> , 2001 , 8, 81-3	1	6
296	Cyclooxygenase-2 selective inhibitors and the kidney. 2001 , 7, 393-400		35
295	Cyclooxygenase-2 and antagonists in pain management. 2001 , 14, 527-32		8
294	Renal effects of cyclooxygenase-2 selective inhibitors. 2001 , 10, 603-10		17
293	COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study. 2001 , 7, 151-9		35
292	Risques rñaux des anti-inflammatoires non stñroïdiens COX 2 slectifs. 2001 , 14, 163-167		
291	Recent advances in pain management in palliative care. 2001 , 12, 296-301		1
290	Therapeutic potential of COX-2 inhibitors in arthritis. 2001 , 10, 1317-25		3
289	Klinische Studien zum selektiven Cyclooxygenase-2-Inhibitor Celecoxib. 2001 , 26, 75-81		2
288	COX-2 inhibitors compared and contrasted. 2001 , 2, 1859-76		11
287	High blood pressure in the geriatric population: treatment considerations. 2002 , 11, 223-32		20
286	[Are COX-2 inhibitors a risk factor for cardiovascular disease?]. 2002 , 127, 156-9		1

285	Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. 2002 , 39, 929-34		123
284	Key questions concerning paracetamol and NSAIDs for osteoarthritis. 2002 , 61, 767-73		35
283	Cyclooxygenase inhibition: between the devil and the deep blue sea. 2002 , 50 Suppl 3, III25-30		30
282	Cyclooxygenase-2 inhibition and cardiovascular events. 2002 , 106, 167-9		76
281	The Renal Effects of Traditional Nonsteroidal Anti-Inflammatory Agents Versus Cyclooxygenase-2 Inhibitors. 2002 , 15, 383-391		
280	Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects. 2002 , 4, 268-75		14
279	Use of nonopioid analgesics and adjunctive agents in the management of pain in rheumatic diseases. 2002 , 14, 63-71		18
278	Areas of emerging interest in analgesia: cardiovascular complications. <i>American Journal of Therapeutics</i> , 2002 , 9, 259-69	1	18
277	Cyclooxygenase inhibition for postoperative analgesia. 2002 , 95, 169-76		57
276	Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?. 2002 , 14, 225-30		18
275	Recent developments in toxic nephropathy. 2002 , 11, 155-63		12
274	Anti-inflammatory and antipyretic analgesics and drugs used in gout. 2002 , 25, 126-138		
273	Cox-2 inhibitors: today and tomorrow. 2002 , 323, 181-9		46
272	Oral and intra-articular remedies: Review of papers published from March 2001 to February 2002. 2002 , 14, 597-602		1
271	Worsening heart failure associated with COX-2 inhibitors. 2002 , 112, 424-6		9
270	Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?. 2002 , 25, 829-35		16
269	A new role for opioids in the treatment of arthritis. 2002 , 62, 255-63		13
268	Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. 2002 , 62, 1599-609		31

267	Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug. 2002 , 22, 799-818	47
266	[First spontaneous reports of adverse drug reactions to the new selective COX-2 non-steroid anti-inflammatory drugs]. 2002 , 119, 516; author reply 517-8	
265	Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration. 2002 , 31, 337-44	16
264	Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?. 2002 , 1, 45-52	9
263	Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. 2002 , 24, 969-89	7
262	The authors reply. 2002 , 24, 469-470	1
261	Factores que influyen en la hipertensi3n arterial refractaria. 2002 , 19, 163-171	1
260	[First spontaneous reports of adverse drug reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs]. 2002 , 119, 516-7; author reply 517-8	1
259	[Benefits and risks of cyclooxygenase-2-selective inhibitor nonsteroidal antiinflammatory drugs]. 2002 , 119, 429-34	5
258	[Are COX-2 inhibitors indicated for patients at risk?]. 2002 , 29, 230-2	1
257	Considerations for the safe prescribing and use of COX-2-specific inhibitors. 2002 , 176, 328-31	21
256	Challenges of managing chronic pain in the elderly. 2002 , 32, 43-50	17
255	Anti-inflammatory agents and renal function. 2002 , 32, 33-42	91
254	Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. 2002 , 89, 425-30	197
253	Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. 2002 , 90, 959-63	264
252	Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. 2002 , 63, 817-21	103
251	The demographics of chronic pain management. 2002 , 24, S10-7	1
250	Is there a place for non-selective NSAIDs in the treatment of arthritis?. 2002 , 69, 4-7	6

249	[Specificity, action, indications and safety. Criteria for the use of COX-2 inhibitors]. 2002 , 31, 190-8	
248	The Feng Pao Hsii Lecture. 2002 , 5, 41-47	
247	Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection. 2002 , 768, 255-60	27
246	Les anti-inflammatoires non stéroïdiens non spécifiques de la COX-2 ont-ils encore une place dans le traitement des maladies articulaires ?. 2002 , 69, 4-7	3
245	Renal effects of cyclo-oxygenase-2 inhibition. 2002 , 7, 281-286	4
244	Cyclo-oxygenase-2 inhibition increases blood pressure in rats. 2002 , 136, 1117-26	63
243	Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. 2002 , 72, 50-61	105
242	Cyclooxygenase-2 inhibitors. 2003 , 96, 1720-1738	59
241	Cyclo-oxygenase 2 inhibitors: emerging roles in the gut. 2003 , 18, 279-91	22
240	Nonsteroidal anti-inflammatory drugs in patients with cardio- or cerebrovascular disorders. 2003 , 92, 721-9	17
239	Opioid and non-opioid analgesics. 2003 , 17, 91-110	34
238	Are cyclooxygenase-2-selective inhibitors safe for the kidneys?. 2003 , 70, 237-41	3
237	Coxibs--beyond the GI tract: renal and cardiovascular issues. 2003 , 25, S41-9	31
236	Analgesia in patients with ESRD: a review of available evidence. 2003 , 42, 217-28	117
235	Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib. 2003 , 23, 1416-23	11
234	Quân est-il de la tolñance rñale des coxibs ?. 2003 , 70, 545-549	4
233	Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. 2003 , 253, 643-52	155
232	[Cyclooxygenase 2 selective antirheumatic analgesics]. 2003 , 153, 100-3	1

231	Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. 2003 , 17, 321-32	52
230	[Clinical trials with rofecoxib: analysis of the information from the gender perspective]. 2003 , 120, 207-12	9
229	Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. 2003 , 42, 545-56	22
228	Nonsteroidal anti-inflammatory drugs and heart failure. 2003 , 63, 525-34	92
227	A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. 2003 , 25, 647-62	7
226	Interventions in chronic pain management. 4. Medications in pain management. 2003 , 84, S50-6	4
225	Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. 2003 , 16, 135-9	36
224	Current pharmacotherapy for the treatment of severe burns. 2003 , 4, 369-84	68
223	The role of opioid analgesics in rheumatoid disease in the elderly population. 2003 , 20, 571-83	6
222	Clinical Nephrotoxins. 2003 ,	6
221	Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2003 , 42, 1206-52	10207
220	Adverse Drug Events Involving COX-2 Inhibitors. 2003 , 37, 1203-13	26
219	Effect of cyclooxygenase-2 inhibitors on blood pressure. 2003 , 37, 442-6	10
218	The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. 2003 , 42 Suppl 3, iii40-52	41
217	Advances in Modelling and Clinical Application of Intravenous Anaesthesia. 2003 ,	
216	Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation. 2003 , 304, 1153-60	39
215	Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. 2003 , 52, 600-8	117
214	Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. 2003 , 42, 1332-41	13

213	A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain. 2003 , 42, 141-8		63
212	A retrospective review of the effect of COX-2 inhibitors on blood pressure change. <i>American Journal of Therapeutics</i> , 2003 , 10, 311-7	1	21
211	Patient perception of the burden of weight gain and blood pressure increase among RA patients using celecoxib, rofecoxib, and non-specific NSAIDs. 2003 , 9, 344-53		4
210	Audit of Celecoxib and Rofecoxib Use: St Vincent's Public Hospital, Darlinghurst. 2003 , 33, 74-77		0
209	Pharmacology of COX-2 inhibitors. 2003 , 37, 25-51		3
208	COX-2 Inhibitors: Effects on Blood Pressure in a Veterans Affairs Medical Center. 2003 , 38, 556-564		1
207	Interaction of rofecoxib and celecoxib with warfarin. 2003 , 60, 1319-23		15
206	Non-Steroidal Anti-Inflammatory Drug-Related Gastroduodenal Damage in the Elderly. 2003 , 32, 118-127		
205	NSAIDs: gastroprotection or selective COX-2 inhibitor?. 2004 , 18, 275-86		20
204	Pharmacology and toxicology of COX-2 inhibitors. 2004 , 67-131		1
203	Acute congestive heart failure induced by rofecoxib. 2004 , 17, 131-5		5
202	Blood Pressure Elevation with Rofecoxib in Older Adults. 2004 , 20, 80-84		
201	Effects on the kidney: role of COX-2 inhibitors. 2004 , 179-194		
200	Cyclooxygenases, the kidney, and hypertension. 2004 , 43, 525-30		133
199	Renal cyclooxygenase-2 (COX-2). Physiological, pathophysiological, and clinical implications. 2004 , 27, 43-62		27
198	Osteoarthritis therapy--are there still unmet needs?. 2004 , 43 Suppl 1, i9-15		25
197	Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. 2004 , 44, 424-8		94
196	COX-2 Inhibitors. 2004 ,		4

195	Relationship between COX-2 specific inhibitors and hypertension. 2004 , 44, 140-5	117
194	Cardiovascular complications of COX2 selective inhibitors cause considerable concern. 2004 , 13, 260-1	3
193	Complications rñales des anti-inflammatoires non stñroïdiens. 2004 , 71, S167-S172	
192	[Pain treatment in geriatric patients]. 2004 , 43, W321-30; quiz W331-2	1
191	Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study. 2004 , 60, 489-501	10
190	Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. 2004 , 13, 277-87	24
189	Aging and upper gastrointestinal disorders. 2004 , 18 Suppl, 73-81	53
188	Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. 2004 , 18, 790-804	482
187	The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. 2004 , 43, 985-90	102
186	Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. 2004 , 47, 550-7	381
185	Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis. 2004 , 27, 185-96	7
184	Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). 2004 , 24, 227-36	8
183	Acute Pulmonary Oedema Induced by COX-2 Inhibitors in a Patient with Chronic Pain. 2004 , 24, 491-2	0
182	Pharmacological treatments for persistent non-malignant pain in older persons. 2004 , 21, 19-41	49
181	Relationship between cyclooxygenase-2 inhibition and thrombogenesis. 2004 , 9, 51-9	9
180	Cardiovascular effects of selective cyclooxygenase-2 inhibitors. 2004 , 2, 265-70	26
179	In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. 2004 , 47, 792-804	70
178	Papel de los inhibidores selectivos de la COX-2 en la hipertensiñ arterial. 2004 , 21, 30-37	

177	Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. 2004 , 109, 514-519	298
176	[Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective cox 2 inhibitors]. 2004 , 33, 483-9	11
175	Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. 2004 , 363, 1751-6	355
174	Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. 2004 , 364, 675-84	399
173	Dosing of antirheumatic drugs in renal disease and dialysis. 2004 , 10, 190-204	10
172	Keeping your patient with heart failure safe: a review of potentially dangerous medications. 2004 , 164, 709-20	46
171	Antiplatelet agents and anticoagulants for hypertension. 2004 , CD003186	17
170	The cardiovascular safety of celecoxib. 2005 , 1, 709-22	
169	Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. 2005 , 142, 157-64	160
168	Rofecoxib for rheumatoid arthritis. 2005 , CD003685	21
167	COX-2 controversy: where are we and where do we go from here?. 2005 , 13, 395-402	14
166	Introduction - The coxib controversies. 2005 , 13, 331-41	16
165	Cardiovascular risk and COX-2 inhibition in rheumatological practice. 2005 , 19, 1-5	38
164	Antithrombotic therapy in hypertension: a Cochrane Systematic review. 2005 , 19, 185-96	20
163	The Editor's roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk. 2005 , 96, 1589-604	17
162	Role of cyclooxygenase-2 inhibitors in postoperative pain management. 2005 , 23, 49-72	21
161	Comorbid conditions in the AMICA study patients: effects on the quality of life and drug prescriptions by general practitioners and specialists. 2005 , 35, 31-7	58
160	Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. 2005 , 53, 12-7	25

159	[Pain assessment and pain treatment in the geriatric patient. Part II: pain treatment]. 2005 , 19, 65-73	5
158	An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors. 2005 , 9, 377-89	13
157	Perception of risk: the state of COX-2 selective inhibitors. 2005 , 7, 163-6	2
156	A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. 2005 , 23, 583-90	80
155	Global safety of coxibs and NSAIDs. 2005 , 5, 465-73	24
154	Adverse interactions of rofecoxib with lisinopril in spontaneously hypertensive rats. 2005 , 43, 361-73	5
153	Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. 2005 , 11, 1795-804	106
152	The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. 2005 , 165, 161-8	183
151	Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?. 2005 , 45, 92-7	36
150	Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. 2005 , 57, 217-52	283
149	Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. 2005 , 44, 677-80	116
148	Celecoxib and cardiovascular risks. 2005 , 4, 1005-15	48
147	Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. 2005 , 352, 1092-102	2043
146	Blood pressure in Native Americans switched from celecoxib to rofecoxib. 2005 , 39, 797-802	6
145	Postoperative NSAIDs and COX-2 inhibitors: cardiovascular risks and benefits. 2005 , 95, 281-4	18
144	Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. 2005 , 21, 47-60	15
143	Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. 2005 , 165, 490-6	229
142	Hipertensi3n arterial en las enfermedades autoinmunes y sist3micas. 2005 , 22, 21-31	2

141	Are all COX-2 inhibitors created equal?. 2005 , 45, 178-80		9
140	Rofecoxib for osteoarthritis. 2005 , CD005115		12
139	Hipertensi3n arterial en las enfermedades autoinmunes y sist3micas. 2005 , 22, 21-31		
138	Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. 2005 , 7 Suppl 4, S14-22		52
137	[What do we know about the cardiovascular toxicity of the NSAIDs?]. 2006 , 35 Suppl 1, 11-23		3
136	Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. 2006 , 29, 621-32		69
135	Clinical practice. Resistant or difficult-to-control hypertension. 2006 , 355, 385-92		169
134	Selective cyclooxygenase inhibition: its role in pain and anaesthesia. 2006 , 60, 323-8		42
133	Drug interactions and drugs that affect blood pressure. 2006 , 8, 731-7		36
132	Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial. <i>American Journal of Therapeutics</i> , 2006 , 13, 229-35	1	11
131	Blood pressure effects of COX-2 inhibitors. 2006 , 47 Suppl 1, S43-8		15
130	Effect of Exercise on Blood Pressure in Older Persons: A Randomized Controlled Trial. 2006 , 2006, 53-55		
129	COX-2 and the kidney. 2006 , 47 Suppl 1, S37-42		98
128	The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. 2006 , 15, 852-60		5
127	Effect of indomethacin and selective cyclooxygenase-2 inhibitors on proteinuria and renal function in patients with AA type renal amyloidosis. 2006 , 11, 232-7		3
126	Paracetamol: new vistas of an old drug. 2006 , 12, 250-75		361
125	Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. 2006 , 62, 345-57		55
124	COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. 2006 , 5, 75-86		196

123	Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. 2006 , 70, 1495-502		39
122	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?. 2006 , 373, 1-17		28
121	The problem of polypharmacy in heart failure. 2006 , 8, 217-25		22
120	Clinical implications of nonopioid analgesia for relief of mild-to-moderate pain in patients with or at risk for cardiovascular disease. 2006 , 97, 3-9		20
119	Nonnarcotic analgesics and hypertension. 2006 , 97, 10-6		64
118	More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. 2006 , 54, 282-91		41
117	Update on cyclooxygenase-2 inhibitors. 2006 , 1, 236-45		51
116	Microbial flora in NSAID-induced intestinal damage: a role for antibiotics?. 2006 , 73 Suppl 1, 136-50		67
115	Are there differences in the renal effects of selective cyclo-oxygenase 2 inhibitors?. 2006 , 2, 174-5		1
114	Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal. 2006 , 6, 1643-55		21
113	COX-2 inhibitors celecoxib and parecoxib: valuable options for postoperative pain management. 2007 , 7, 235-49		19
112	Dual carbonic anhydrase--cyclooxygenase-2 inhibitors. 2007 , 7, 885-91		39
111	Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs. <i>American Journal of Therapeutics</i> , 2007 , 14, 3-12	1	14
110	Celecoxib: a review of its use in the management of arthritis and acute pain. 2007 , 67, 2433-72		67
109	Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. 2007 , 5, 818-28, 828.e1-5; quiz 768		189
108	Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis. 2007 , Volume 2, 0-0		
107	Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. 2007 , 16, 891-900		32
106	Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. 2007 , 16, 762-72		54

105	Quality indicators for the care of hypertension in vulnerable elders. 2007 , 55 Suppl 2, S359-65	12
104	Changes in pain, stiffness and physical function in patients with osteoarthritis waiting for hip or knee joint replacement surgery. 2007 , 15, 837-43	35
103	Coxibs and NSAIDs--is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. 2007 , 15, 849-56	13
102	Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. 2008 , 61, 283-9	17
101	Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. 2008 , 59, 1058-73	99
100	Nonsteroidal anti-inflammatory drugs and the heart: what is the danger?. 2008 , 14, 75-82	10
99	A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen. 2008 , 10, 592-602	7
98	COX-2 selective inhibitors in the treatment of osteoarthritis. 2008 , 38, 165-87	79
97	Non-steroidal anti-inflammatory drugs. 2008 , 419-457	2
96	Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?. 2008 , 2, 53-66	16
95	Hypertension in rheumatoid arthritis. 2008 , 47, 1286-98	197
94	Carbonic anhydrase inhibition: insight into non-COX-2 pharmacological effect of some coxibs. 2008 , 14, 679-84	8
93	Cardiovascular effects of cyclooxygenase-2 inhibitors. 2007 , 23, 617-24	5
92	Dual Carbonic Anhydrase and Cyclooxygenase-2 Inhibition. 255-272	
91	Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. 2009 , 1, 47-71	43
90	Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. 2009 , 36, 1290-7	42
89	Pharmacological management of persistent pain in older persons. 2009 , 10, 1062-83	119
88	Pharmacological management of persistent pain in older persons. 2009 , 57, 1331-46	814

87	A randomized, double-blind, placebo-controlled trial of a selective COX-2 inhibitor, GW406381, in patients with postherpetic neuralgia. 2009 , 10, 654-60	16
86	Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. 2009 , 27, 2332-41	77
85	Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. 2010 , 18, 204-12	78
84	Nonsteroidal Anti-Inflammatory Drugs and the Kidney. 2010 , 3, 2291-2321	123
83	Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. 2003 , 55, 859-94	24
82	Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?. 2010 , 12, 258-66	10
81	Celecoxib activates PI-3K/Akt and mitochondrial redox signaling to enhance heme oxygenase-1-mediated anti-inflammatory activity in vascular endothelium. 2010 , 48, 1013-23	55
80	Conservative treatment modalities and outcomes for osteoarthritis: the concomitant pyramid of treatment. 2010 , 38, 133-45	14
79	Pathophysiology of cyclooxygenases in cardiovascular homeostasis. 2010 , 47, 601-13	21
78	The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. 2010 , 2010, 215158	295
77	Treatment of osteoarthritis in hypertensive patients. 2010 , 11, 393-403	17
76	Antiplatelet agents and anticoagulants for hypertension. 2011 , CD003186	13
75	Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. 2011 , 71, 2457-89	141
74	Cardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis. 2011 , 2011, 862153	12
73	Nonsteroidal anti-inflammatory drugs. 548-562	
72	The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. 2011 , 19, 184-91	49
71	Managing Headache in Older People. 2011 , 591-607	
70	Renal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial. 2011 , 4, 2	6

69	Low-dose acetylsalicylic acid and blood pressure control in drug-treated hypertensive patients. 2011 , 18, 136-40	3
68	Nonsteroidal anti-inflammatory drugs and their effects in the elderly. 2012 , 8, 167-177	9
67	Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. 2012 , 12, 93	48
66	Communications affichees. 2012 , 79, A133-A334	
65	5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity. 2012 , 29, 79-98	34
64	Towards developing new strategies to reduce the adverse side-effects of nonsteroidal anti-inflammatory drugs. 2012 , 16, 25-9	18
63	Management of Hyperuricemia and Gout. 2013 , 291-385	
62	Etoricoxib attenuates effect of antihypertensives in a rodent model of DOCA-salt induced hypertension. 2013 , 35, 601-6	4
61	Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. 2013 , 16, 821-47	364
60	Cardiovascular risk and inhibition of cyclooxygenase: traditional nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors. 2013 , 37-54	
59	Risk of stroke associated with nonsteroidal anti-inflammatory drugs. 2014 , 10, 25-32	31
58	Renal medullary cyclooxygenase-2 and (pro)renin receptor expression during angiotensin II-dependent hypertension. 2014 , 307, F962-70	28
57	A general catalytic hydroamidation of 1,3-dienes: atom-efficient synthesis of N-allyl heterocycles, amides, and sulfonamides. 2014 , 53, 1630-5	45
56	Treating chronic non-cancer pain in older people--more questions than answers?. 2014 , 79, 34-40	9
55	A General Catalytic Hydroamidation of 1,3-Dienes: Atom-Efficient Synthesis of N-Allyl Heterocycles, Amides, and Sulfonamides. 2014 , 126, 1656-1661	19
54	Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. 2015 , 66, 524-33	47
53	Celecoxib prevents curcumin-induced apoptosis in a hematopoietic cancer cell model. 2015 , 54, 999-1013	9
52	Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease. 2015 , 693-705	

51	COX-2 inhibitors (coxibs). 2016 , 738-762	0
50	Is the cardiovascular toxicity of NSAIDs and COX-2 selective inhibitors underestimated in patients with haemophilia?. 2016 , 100, 25-31	5
49	Adverse Effects of Nonsteroidal Anti-inflammatory Drugs on the Cardiovascular System. 2016 , 61-89	1
48	Drug-Induced Hypertension in Chronic Kidney Disease. 2016 , 261-298	
47	Short-term use of nonsteroidal anti-inflammatory drugs and adverse effects: An updated systematic review. 2016 , 147, 98-110	20
46	Association of Nonsteroidal Anti-inflammatory Drug Use With Stroke Among Dialysis Patients. 2017 , 2, 400-409	5
45	Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. 2018 , 130, 55-71	35
44	The effect of celecoxib on blood pressure and plasma oxidant/antioxidant status in co-administration with glucocorticoid in rat. 2018 , 108, 1804-1808	4
43	Coadministration of lithium and celecoxib reverses manic-like behavior and decreases oxidative stress in a dopaminergic model of mania induced in rats. 2019 , 9, 297	9
42	Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?. 2019 , 20,	16
41	Cardio-renal safety of non-steroidal anti-inflammatory drugs. 2019 , 44, 373-391	25
40	Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs. 2019 , 41, 124-130	63
39	Nonsteroidal Antiinflammatory Drugs and Opioids in Chronic Kidney Disease. 2020 , 1071-1092	1
38	Aspirin used for venous thromboembolism prophylaxis in total hip arthroplasty decreases heterotopic ossification. 2020 , 6, 206-209	4
37	The clinical and endoscopic aspects of peptic ulcers secondary to the use of nonsteroidal anti-inflammatory drugs of various origins. 2021 , 38, 170	1
36	Non-steroidal anti-inflammatory drugs. 2003 , 279-306	4
35	Pharmacology and clinical action of COX-2 selective NSAIDs. 2003 , 523, 201-14	5
34	Iatrogenic and Drug-Induced Hypertension. 2004 , 21-35	3

33	Nonsteroidal Anti-inflammatory Drugs. 2009 , 833-861	2
32	Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. 2002 , 110, 61-69	179
31	Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. 2002 , 110, 61-9	74
30	COX-2 inhibitors for the prevention of heterotopic ossification after THA. 2011 , 34, 467	28
29	Incidence of Heterotopic Ossification Following a Multimodal Pain Protocol in Total Hip Arthroplasty With the Posterior Approach. 2018 , 41, e92-e97	8
28	Anti-inflammatory medications: selective COX-2 inhibitors. 2002 , 10, 75-8	12
27	Stellung der COX II-Hemmer in der Therapie der RA im Vergleich zu konventionellen NSAR. 2002 , 40-43	
26	Refractory Hypertension. 2004 , 3-20	
25	COX-2 inhibitors. 2006 , 1000-1015	
24	Influence of Sibutramine on Blood Pressure: Evidence From Placebo-Controlled Trials. 2006 , 2006, 51-53	
23	Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials. 2007 , 2007, 55-57	
22	Resistant Hypertension. 2007 , 498-511	
21	A pharmacist's perspective: Proceedings from the Third Canadian Consensus Conference: An Evidence-Based Approach to Prescribing NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis. 2007 , 140, 244-253	
20	Nonsteroidal Antiinflammatory Drugs. 2008 , 113-128	
19	OSTEOARTHRITIS: ETIOLOGY, PATHOGENESIS, AND TREATMENT. 2009 , 241-244	
18	ADVERSE CARDIOVASCULAR EFFECTS OF NON-CARDIOVASCULAR DRUGS. 2009 , 557-820	
17	NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs). 2010 , 223-369	
16	Taste Preformulation studies a view to develop fast release solid dosage form.. 2010 , 2, 32-36	

15	Arachidonic Acid Metabolites and the Kidney. 2011 , 421-462	
14	Cardiovascular System. 180-227	
13	[Clinical guidelines "Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice". Part I]. 2015 , 115, 70-82	1
12	Selective COX-2 inhibitors Safety and side-effects. 39-53	
11	Management of Hypertension in Older Patients With Arthritis. 2005 , 471-489	
10	COX-2 inhibitors in the treatment of cardiovascular disease. 2002 , 167, 738-9; author reply 739-40	
9	COX-2 inhibitors and type 4 error. 2003 , 169, 190	1
8	Rheumatology and musculoskeletal medicine. 2004 , 54, 457-64	5
7	Safe pharmacologic treatment strategies for osteoarthritis pain in African Americans with hypertension, and renal and cardiac disease. 2006 , 98, 1126-35	4
6	Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis. 2007 , 2, 131-50	1
5	Review of the cardiovascular safety of COXIBs compared to NSAIDs. 2008 , 19, 102-7	32
4	The Effects of Pain and Analgesic Medications on Blood Pressure.	2
3	Antiplatelet agents and anticoagulants for hypertension. 2022 , 2022,	1
2	Toxic Nephropathies. 2022 , 311-327	0
1	Clinical trials and future perspectives of antiinflammatory agents. 2023 , 331-386	0